Impact of Treatment with Biologic DMARDs on the Risk of Sepsis or Mortality After Serious Infection in Patients with Rheumatoid Arthritis

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2015 Nov 15

PMID 26567181

Citations 45

Authors

A Richter

J Listing

M Schneider

T Klopsch

A Kapelle

J Kaufmann

A Zink

A Strangfeld

Affiliations

Soon will be listed here.

Abstract

Objective: This observational cohort study investigated the impact of biological (b) disease-modifying antirheumatic drugs (DMARDs) on the outcomes of serious infections (SIs) in patients with rheumatoid arthritis.

Methods: We investigated outcomes of SIs observed in 947 patients enrolled in the German biologics register RABBIT(Rheumatoid arthritis: observation of biologic therapy). Outcomes were (1) recovery without complication, (2) sepsis following SI (≤30 days), and (3) death after SI without known sepsis (≤90 days). We applied a multinomial generalised estimating equation model for longitudinal data to evaluate the risks of sepsis and death simultaneously.

Results: Sepsis within 30 days after SI was reported in 135 out of 947 patients, 85 of these had a fatal outcome. Fifty-three patients died within 90 days after SI without known sepsis. The adjusted risk of developing sepsis increased with age and was higher in patients with chronic renal disease. Compared with conventional synthetic (cs)DMARDs, the risk was significantly lower when patients were exposed to bDMARDs at the time of SI (OR: 0.56, 95% CI 0.38 to 0.81). Risk factors of fatal SI were higher age, use of glucocorticoids at higher doses and heart failure. Patients treated with bDMARDs and those with better physical function had a significantly lower mortality risk.

Conclusions: These results suggest a beneficial effect of bDMARDs on the risk of sepsis after SI and the risk of a fatal outcome. Successful immunosuppression may prevent an unregulated host response to SI, that is, the escalation to sepsis. Further investigation is needed to validate these results.

Citing Articles

[Rheumatological care in Germany : Memorandum of the German Society for Rheumatology and Clinical Immunology 2024].

Braun J, Albrecht K, Callhoff J, Haase I, Krause A, Lakomek H Z Rheumatol. 2024; 83(Suppl 2):249-284.

PMID: 39136764 DOI: 10.1007/s00393-024-01539-2.

PDIA3 orchestrates effector T cell program by serving as a chaperone to facilitate the non-canonical nuclear import of STAT1 and PKM2.

Yang C, Wang F, Luo J, Rong S, Lu W, Chen Q Mol Ther. 2024; 32(8):2778-2797.

PMID: 38822524 PMC: 11405166. DOI: 10.1016/j.ymthe.2024.05.038.

Predictive performance of NEWS and qSOFA in immunocompromised sepsis patients at the emergency department.

Boekhoud L, Schaap H, Huizinga R, Olgers T, Ter Maaten J, Postma D Infection. 2024; 52(5):1863-1873.

PMID: 38607592 PMC: 11499318. DOI: 10.1007/s15010-024-02247-4.

Effect of tumour necrosis factor-a inhibitors exposure on surgical site infections in rheumatoid arthritis patients undergoing elective orthopaedic surgery: A meta-analysis.

Liu X, Wei C, Wang J, Li M Int Wound J. 2024; 21(1):e14538.

PMID: 38272825 PMC: 10788641. DOI: 10.1111/iwj.14538.

Antimicrobial stewardship and targeted therapies in the changing landscape of maternal sepsis.

Shah N, Charani E, Ming D, Cheah F, Johnson M J Intensive Med. 2024; 4(1):46-61.

PMID: 38263965 PMC: 10800776. DOI: 10.1016/j.jointm.2023.07.006.

References

Lautenschlager J, Mau W, Kohlmann T, Raspe H, Struve F, Bruckle W . [Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire]. Z Rheumatol. 1997; 56(3):144-55. DOI: 10.1007/s003930050030. View

Beutler B, Milsark I, Cerami A . Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985; 229(4716):869-71. DOI: 10.1126/science.3895437. View

Lee S, Kim W . Dual effects of tumor necrosis factor α inhibitors on septic arthritis: from a "bad friend" to a "good enemy". Arthritis Rheumatol. 2014; 67(1):11-3. DOI: 10.1002/art.38903. View

Bongartz T, Sutton A, Sweeting M, Buchan I, Matteson E, Montori V . Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295(19):2275-85. DOI: 10.1001/jama.295.19.2275. View

Tracey K, Fong Y, Hesse D, Manogue K, Lee A, Kuo G . Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987; 330(6149):662-4. DOI: 10.1038/330662a0. View

Abraham E, Laterre P, Garbino J, Pingleton S, Butler T, Dugernier T . Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med. 2001; 29(3):503-10. DOI: 10.1097/00003246-200103000-00006. View

Cohen J . The immunopathogenesis of sepsis. Nature. 2002; 420(6917):885-91. DOI: 10.1038/nature01326. View

Waage A . Tumour necrosis factor and septic shock. Lancet. 1998; 351(9102):603. DOI: 10.1016/S0140-6736(05)78598-6. View

Brown E . Using MedDRA: implications for risk management. Drug Saf. 2004; 27(8):591-602. DOI: 10.2165/00002018-200427080-00010. View

10.

Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K . Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis. 2005; 64(9):1274-9. PMC: 1755655. DOI: 10.1136/ard.2004.031476. View

11.

Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M . Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005; 52(11):3403-12. DOI: 10.1002/art.21386. View

12.

Andersen P, Abildstrom S, Rosthoj S . Competing risks as a multi-state model. Stat Methods Med Res. 2002; 11(2):203-15. DOI: 10.1191/0962280202sm281ra. View

13.

Schorr C, Zanotti S, Dellinger R . Severe sepsis and septic shock: management and performance improvement. Virulence. 2013; 5(1):190-9. PMC: 3916373. DOI: 10.4161/viru.27409. View

14.

Waage A, Halstensen A, Espevik T . Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987; 1(8529):355-7. DOI: 10.1016/s0140-6736(87)91728-4. View

15.

Reinhart K, Karzai W . Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med. 2001; 29(7 Suppl):S121-5. DOI: 10.1097/00003246-200107001-00037. View

16.

Fisher Jr C, Opal S, Dhainaut J, Stephens S, Zimmerman J, Nightingale P . Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med. 1993; 21(3):318-27. DOI: 10.1097/00003246-199303000-00006. View

17.

Listing J, Gerhold K, Zink A . The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2012; 52(1):53-61. DOI: 10.1093/rheumatology/kes305. View

18.

Strangfeld A, Eveslage M, Schneider M, Bergerhausen H, Klopsch T, Zink A . Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Ann Rheum Dis. 2011; 70(11):1914-20. PMC: 3184240. DOI: 10.1136/ard.2011.151043. View

19.

Galloway J, Hyrich K, Mercer L, Dixon W, Fu B, Ustianowski A . Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with.... Rheumatology (Oxford). 2010; 50(1):124-31. PMC: 3105607. DOI: 10.1093/rheumatology/keq242. View

20.

Ali A, Zhu X, Kwiecinski J, Gjertsson I, Lindholm C, Iwakura Y . Antibiotic-killed Staphylococcus aureus induces destructive arthritis in mice. Arthritis Rheumatol. 2014; 67(1):107-16. DOI: 10.1002/art.38902. View